{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:32:50Z","timestamp":1790137970699,"version":"4.0.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2017S"],"award-info":[{"award-number":["RIA2017S"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Initiative on HIV Prevention Technology","award":["RIA2017S"],"award-info":[{"award-number":["RIA2017S"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally. Early studies on bnAbs showed safety in humans, but short elimination half-lives and low potency and breadth. Since 2010, several new highly potent bnAbs have been assessed in clinical trials alone or in combination for HIV prevention. Published data indicate that these bnAbs are safe and have a half-life ranging from 15 to 71 days. Only intravenous VRC01 has advanced to an efficacy trial, with results expected in late 2020. If bnAbs are shown to be effective in preventing HIV infection, they could fast-track vaccine development as correlates of protection, and contribute as passive immunization to achieving the goal of epidemic control. The purpose of the current review is to describe the current status and provide a synopsis of the available data on bnAbs in clinical trials for HIV prevention.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa377","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T19:15:23Z","timestamp":1592939723000},"page":"370-380","source":"Crossref","is-referenced-by-count":80,"title":["Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review"],"prefix":"10.1093","volume":"223","author":[{"given":"Sharana","family":"Mahomed","sequence":"first","affiliation":[{"name":"CAPRISA, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Garrett","sequence":"additional","affiliation":[{"name":"CAPRISA, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa"},{"name":"Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Baxter","sequence":"additional","affiliation":[{"name":"CAPRISA, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quarraisha","family":"Abdool Karim","sequence":"additional","affiliation":[{"name":"CAPRISA, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa"},{"name":"Department of Epidemiology, Mailman School of Public Health, Columba University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S","family":"Abdool Karim","sequence":"additional","affiliation":[{"name":"CAPRISA, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa"},{"name":"Department of Epidemiology, Mailman School of Public Health, Columba University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"2021101216334997000_CIT0001","volume-title":"Miles to go: closing gaps, breaking barriers, righting injustices","author":"UNAIDS","year":"2018"},{"key":"2021101216334997000_CIT0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","article-title":"Broadly neutralizing antibodies for HIV eradication","volume":"13","author":"Stephenson","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2021101216334997000_CIT0003","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp1802256","article-title":"Monoclonal antibodies for emerging infectious diseases\u2014borrowing from history","volume":"378","author":"Marston","year":"2018","journal-title":"N Engl J Med"},{"key":"2021101216334997000_CIT0004","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37(suppl 1)","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"2021101216334997000_CIT0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of broadly neutralizing antibodies for HIV-1 prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol Rev"},{"key":"2021101216334997000_CIT0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12977-018-0453-y","article-title":"The expanding array of HIV broadly neutralizing antibodies","volume":"15","author":"McCoy","year":"2018","journal-title":"Retrovirology"},{"key":"2021101216334997000_CIT0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12977-018-0455-9","article-title":"Antibody-mediated prevention and treatment of HIV-1 infection","volume":"15","author":"Gruell","year":"2018","journal-title":"Retrovirology"},{"key":"2021101216334997000_CIT0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","article-title":"A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1","volume":"16","author":"Armbruster","year":"2002","journal-title":"AIDS"},{"key":"2021101216334997000_CIT0009","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkh428","article-title":"Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12","volume":"54","author":"Armbruster","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2021101216334997000_CIT0010","doi-asserted-by":"crossref","first-page":"e116153","DOI":"10.1371\/journal.pone.0116153","article-title":"MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"2021101216334997000_CIT0011","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat Med"},{"key":"2021101216334997000_CIT0012","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/pbi.12416","article-title":"Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants","volume":"13","author":"Ma","year":"2015","journal-title":"Plant Biotechnol J"},{"key":"2021101216334997000_CIT0013","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2004.11.012","article-title":"Preventing transmission: plant-derived microbicides and mucosal vaccines for reproductive health","volume":"23","author":"Whaley","year":"2005","journal-title":"Vaccine"},{"key":"2021101216334997000_CIT0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"2021101216334997000_CIT0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"2021101216334997000_CIT0016","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"2021101216334997000_CIT0017","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","article-title":"Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J Exp Med"},{"key":"2021101216334997000_CIT0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.immuni.2019.06.004","article-title":"Rapid and focused maturation of a VRC01-class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-glycan","volume":"51","author":"Umotoy","year":"2019","journal-title":"Immunity"},{"key":"2021101216334997000_CIT0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021101216334997000_CIT0020","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med"},{"key":"2021101216334997000_CIT0021","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"2021101216334997000_CIT0022","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"2021101216334997000_CIT0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2021101216334997000_CIT0024","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"2021101216334997000_CIT0025","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3018(19)30231-0","article-title":"Engineered HIV antibody passes muster","volume":"6","author":"Morris","year":"2019","journal-title":"Lancet HIV"},{"key":"2021101216334997000_CIT0026","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.4049\/jimmunol.178.7.4424","article-title":"The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes","volume":"178","author":"Alam","year":"2007","journal-title":"J Immunol"},{"key":"2021101216334997000_CIT0027","article-title":"Therapeutic activity of PGT121 monoclonal antibody in HIV-infected adults","author":"Stephenson"},{"key":"2021101216334997000_CIT0028","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"2021101216334997000_CIT0029","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat Immunol"},{"key":"2021101216334997000_CIT0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"2021101216334997000_CIT0031","first-page":"461","article-title":"Subcutaneous administration of biotherapeutics: current experience in animal models","volume":"12","author":"McDonald","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"2021101216334997000_CIT0032","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jps.24277","article-title":"Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics","volume":"104","author":"Fathallah","year":"2015","journal-title":"J Pharm Sci"},{"key":"2021101216334997000_CIT0033","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","article-title":"Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration","volume":"4","author":"Zheng","year":"2012","journal-title":"MAbs"},{"key":"2021101216334997000_CIT0034","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"2021101216334997000_CIT0035","first-page":"20160001","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials","volume":"9","author":"Gilbert","year":"2017","journal-title":"Stat Commun Infect Dis"},{"key":"2021101216334997000_CIT0036","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1080\/21645515.2018.1462640","article-title":"Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials","volume":"14","author":"Huang","year":"2018","journal-title":"Hum Vacc Immunother"},{"key":"2021101216334997000_CIT0037","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nm.4063","article-title":"Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques","volume":"22","author":"Hessell","year":"2016","journal-title":"Nat Med"},{"key":"2021101216334997000_CIT0038","doi-asserted-by":"crossref","first-page":"e1001616","DOI":"10.1371\/journal.pmed.1001616","article-title":"HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission","volume":"11","author":"Voronin","year":"2014","journal-title":"PLoS Med"},{"key":"2021101216334997000_CIT0039","article-title":"Safety and pharmacokinetics of a potent anti-HIV monoclonal antibody, VRC01, in HIV-exposed newborns","author":"Cunningham","year":"2017"},{"key":"2021101216334997000_CIT0040","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/S2352-3018(18)30174-7","article-title":"Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1","volume":"5","author":"Jaworski","year":"2018","journal-title":"Lancet HIV"},{"key":"2021101216334997000_CIT0041","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"2021101216334997000_CIT0042","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat Med"},{"key":"2021101216334997000_CIT0043","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/1535370217748575","article-title":"Evolution of the magic bullet: single chain antibody fragments for the targeted delivery of immunomodulatory proteins","volume":"243","author":"Fercher","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"2021101216334997000_CIT0044","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/QAD.0000000000001521","article-title":"Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV","volume":"31","author":"Anderson","year":"2017","journal-title":"AIDS"},{"key":"2021101216334997000_CIT0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/pbi.12360","article-title":"Rice endosperm produces an underglycosylated and potent form of the HIV-neutralizing monoclonal antibody 2G12","volume":"14","author":"Vamvaka","year":"2016","journal-title":"Plant Biotechnol J"},{"key":"2021101216334997000_CIT0046","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/JCM.36.11.3198-3204.1998","article-title":"Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential","volume":"36","author":"De Logu","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2021101216334997000_CIT0047","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.8755-8920.2000.430302.x","article-title":"Anti-sperm antibodies from infertile patients and their cognate sperm antigens: a review. Identity between SAGA-1, the H6-3C4 antigen, and CD52","volume":"43","author":"Diekman","year":"2000","journal-title":"Am J Reproduct Immunol"},{"key":"2021101216334997000_CIT0048","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12977-018-0443-0","article-title":"Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers","volume":"15","author":"Landais","year":"2018","journal-title":"Retrovirology"},{"key":"2021101216334997000_CIT0049","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12981-017-0178-3","article-title":"Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies","volume":"14","author":"Ahmed","year":"2017","journal-title":"AIDS Res Ther"},{"key":"2021101216334997000_CIT0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s41669-019-0157-9","article-title":"Cost-effectiveness of three alternative boosted protease inhibitor-based second-line regimens in HIV-infected patients in west and Central Africa","volume":"4","author":"Boyer","year":"2020","journal-title":"Pharmacoecon Open"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa377\/33563639\/jiaa377.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/3\/370\/40576039\/jiaa377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/3\/370\/40576039\/jiaa377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T22:19:40Z","timestamp":1634509180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/3\/370\/5865449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2021,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa377","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,7,1]]}}}